Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00024622 · ClinicalTrials.gov registry record
PET Scanning in Parkinson s Disease
A clinical trial of Schizophrenia and Parkinson's Disease, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 502
- Enrollment target
- 1
- Study location
NCT00024622 is a study of Schizophrenia and Parkinson's Disease that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 502 participants, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (131% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00024622, a study of Schizophrenia and Parkinson's Disease, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 502 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volunteers, persons with Parkinson s disease (both familial and sporadic), and those with schizophrenia spectrum disorders. The latter also sign consent for NIH approved protocol 89-M-0160, "Inpatient Evaluation of Neuropsychiatric Patients," PI: Daniel Eisenberg, M.D. Using PET with 6-\[F-18\] Fluoro-L-dopa (FDOPA) and (15)0-H2O in a single scan session, both presynaptic dopaminergic function and regional cerebral blood flow (rCBF) are assessed. The kinetic rate constant (Ki) for presynaptic dopaminergic uptake in striatum and other regions is calculated. We compare Ki across subject groups and relate the findings to rCBF. Findings are also related to allelic variation in genes of interest, for determination of which participants sign separate consent for NIH approved protocol 95-M-0150 Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings, PI: Karen F. Berman, MD. We also draw comparisons between subjects with inherited vs. sporadic Parkinson s disease to determine whether the PET phenotype is the same in both groups, and we compare system-level, circuit-based pathophysiology across PD and schizophrenia groups. Each subject is further screened with an MRI to rule out structural abnormalities and also to further delineate areas of interest in the PET scans.
Conditions Studied
Interventions
- DRUG 18F-Fluoro-L-dopa
- DRUG O-15 Water
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 502 participants |
| Start Date | 2002-03-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00024622
The ClinicalTrials.gov registry entry for NCT00024622 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 502 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (131% higher). The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which 18F-Fluoro-L-dopa is the first listed.
NCT00024622 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00024622 about?
NCT00024622 is a clinical study titled "PET Scanning in Parkinson s Disease". This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volunteers, persons with Parkinson s disease (both familial and sporadic), and those with schizophrenia spectrum disorders. The latter also sign consent for NIH approved protocol 89-M-0...
What is the current status of trial NCT00024622?
This trial is currently completed. The enrollment target is 502 participants. The study started on 2002-03-15.
What conditions does trial NCT00024622 study?
This clinical trial studies the following conditions: Schizophrenia, Parkinson's Disease.
What interventions are being tested in trial NCT00024622?
The interventions under investigation include: 18F-Fluoro-L-dopa (DRUG), O-15 Water (DRUG).
Who is sponsoring clinical trial NCT00024622?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00024622 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.